ReviewFrontiers in bioengineering and biotechnology2025
Fluorescence molecular imaging technology: a promising new strategy for the diagnosis and treatment of gynecologic tumors.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emission-tunable aromatic thiadiazole derivatives based on triphenylimidazole with aggregation-induced emission activity and their application in osteosarcoma imaging.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecologic malignancies such as ovarian, endometrial, and cervical cancers are characterized by challenges in early diagnosis and high therapeutic complexity, creating an urgent need for more precise imaging techniques. Fluorescence molecular imaging, a modality with high sensitivity and high spatial resolution, has demonstrated considerable value in tumor diagnosis and therapy in recent years. Its application in gynecologic oncology is rapidly expanding. By using tumor-specific molecular probes to label neoplastic tissues, this technology enables real-time intraoperative navigation and visualization of tumor lesions and their local features, thereby significantly improving surgical accuracy and therapeutic outcomes. This review summarizes the basic principles of fluorescence imaging, recent advances in molecular probe design, and developments in imaging devices. It places particular emphasis on the value of fluorescence molecular imaging in the diagnosis and precision treatment of gynecologic tumors, aiming to provide systematic theoretical guidance and technical support for related research and clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.